Objectives The use of magnesium sulfate (MgSO4) in European obstetric units is unknown.
We aimed to describe reported policies and actual use of MgSO4 in women delivering …

In women at risk of early preterm imminent birth, from viability to 30 weeks of gestation, use
of MgSO4 for neuroprotection of the fetus is recommended. In pregnancies below 32–34 …

During the last decade, the body of medical knowledge concerning the use of
pharmacological doses of magnesium sulphate (MgSO4) for preterm labour has increased …

Background Intravenous administration of magnesium sulfate (MgSO4) to expectant
individuals before childbirth, has been evaluated to reduce the likelihood of mortality and …

Objective: To provide guidelines for the use of antenatal magnesium sulphate (MgSO4) for
fetal neuroprotection of the preterm infant. Options: Antenatal MgSO4 administration should …

Abstract Background Magnesium sulphate (MgSO 4) is the only treatment approved for fetal
neuroprotection. No information on its use is available in the absence of a national registry …

Objective: The aim of this study was to investigate the effect of maternal magnesium sulfate
(MgSO 4) exposure for eclampsia prophylaxis on neonatal intensive care unit (NICU) …

Abstract Background: Magnesium sulphate (MgSO 4) has been recommended for fetal
neuroprotection to prevent cerebral palsy, with national societies adopting new guidelines …

Magnesium sulfate heptahydrate (MgSO4 7H2O), one of the most commonly used
medications in obstetrics, is an inorganic salt. It is manufactured by dissolution of kieserite in …

OBJECTIVE: To determine whether magnesium sulfate (MgSO4) prophylaxis is needed for
up to 24hours postpartum in all patients with pre-eclampsia. METHODS: In a randomized …